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ABSTRACT 
Background: Inflammatory bowel disease (IBD) is a term that covers ulcerative colitis (UC) 
and Crohn’s disease (CD). The causes of IBD are unknown and the incidence is increasing. 
IBD is a lifelong disease with severe symptoms that affect daily life and Health Related 
Quality of Life (HRQOL). The medical treatment for IBD is complex and many patients 
suffer from side effects of medication. Complementary and Alternative Medicine (CAM) 
encompasses methods that are not a part of conventional healthcare and not generally 
provided by the Swedish healthcare system. The use of CAM is increasing, especially in 
chronic diseases. 
Aim: The overall aim of this thesis was to investigate the use of CAM in patients with IBD 
and to explore attitudes to and experiences of CAM in patients with IBD and healthcare 
professionals (HCPs). An additional aim was to investigate IBD patients’ worries and disease 
related concerns in relation to CAM use. 
Study I was a controlled cross-sectional and multicentre study. The study enrolled 648 
patients with IBD from 12 IBD clinics in Sweden. The control group comprised 440 
individuals selected from Statens Personadressregister (SPAR). Data were collected by 
means of questionnaire. The results revealed that 48.5% (n = 313) of the IBD patients had 
used some form of CAM in the past year, compared with 53.5% (n = 235) in the control 
group. The most common CAM methods used by IBD patients compared to the control group 
were massage 21,3% vs 31,4%, herbal remedies 18,7% vs 21,3%, relaxation 10,5% vs 
11,6%, yoga 8% vs 9,6%, acupuncture 7,6% vs 8,9%, counselling 7,3% vs. 6,2 and 
chiropractic 5,4 vs 5,7%. 
Study II was an interview study in which HCPs were asked to describe their experiences and 
attitudes to CAM. The participants were 16 physicians and nurses who had worked with IBD 
patients for 1-42 years. The results demonstrated that IBD nurses and physicians had 
confidence in and a positive attitude to CAM, especially when used as a complement to 
conventional medicine. The participants were of the opinion that patients considered and 
tested various CAM methods. They stated that CAM has a role in healthcare, which indicates 
acceptance. However, attitudes that constituted an obstacle to CAM were also reported, such 
as lack of evidence. Some participants had a restrictive approach and considered CAM 
unnecessary, while a few were sceptical. 
Study III comprised interviews in which 15 IBD patients described their experiences of 
CAM both alone and in combination with conventional medical treatment. It was found that 
patients with IBD wished to be consulted and have a discussion about CAM. They felt 
disparaged and not taken seriously when they wanted to discuss CAM. HCPs need to be 
aware of this issue in order to meet and understand IBD patients’ needs. The IBD patients 
considered it easier to discuss CAM with nurses than with physicians, which underlines IBD 
nurses’ important role in communicating with and monitoring IBD patients’ use of CAM. 
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patients with IBD wished to be consulted and have a discussion about CAM. They felt 
disparaged and not taken seriously when they wanted to discuss CAM. HCPs need to be 
aware of this issue in order to meet and understand IBD patients’ needs. The IBD patients 
considered it easier to discuss CAM with nurses than with physicians, which underlines IBD 
nurses’ important role in communicating with and monitoring IBD patients’ use of CAM. 
HCPs should be aware that IBD patients consider dietary changes an important CAM 
treatment. 
Study IV was a controlled, cross-sectional and multicentre study. Data from 12 IBD clinics 
in Sweden were collected by means of questionnaires. A total of 645 IBD patients were 
enrolled and asked to answer two questionnaires; a studyspecifik questionnaire concerning 
CAM use, disease and demographic data and the Rating Form of Inflammatory Bowel 
Disease Patients’ Concerns (RFIPC) questionnaire. The RFIPC consists of 25 questions to 
which patients respond by indicating how worried they are about a particular aspect on a 
VAS scale from 0-100. The questionnaire also contains an open question “Is there anything 
more that concerns you?”, which the patients answer in their own words. Of the participants, 
313 used CAM and expressed more concerns in 15 of the 25 RFIPC items compared to 
patients who did not do so/non-users. CAM use was related to younger age and female 
gender. The open question revealed that IBD had a major impact on everyday life and that 
IBD patients’ worry concerned: The family and self, the burden of disease and associated 
factors. 
Conclusion: Patients with IBD used CAM in an attempt to achieve improvement and well-
being. They considered dietary changes an important CAM treatment with positive effects on 
their condition. HCPs attitudes to CAM were mainly positive, although a problematic aspect 
was lack of knowledge and evidence. The HCPs acknowledged their need for education and 
respected the patients’ decision to use CAM. However, patients with IBD reported reluctance 
on the part of HCPs, being treated in a disparaging manner and not taken seriously when 
wishing to discuss CAM. They wanted to be asked about their CAM use and start a dialogue, 
but found it easier to discuss CAM treatment with nurses than physicians. Patients using 
CAM generally had more disease-related concerns compared to those who did not do so. IBD 
affects the whole of everyday life, especially the family and the self. 
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1 INTRODUCTION 
There is a growing interest in Complementary and Alternative Medicine (CAM) in patients 
with chronic diseases; which also applies to those with inflammatory bowel disease (IBD). 
IBD is a lifelong condition with severely disabling symptoms that impact on everyday life [1-
4]. The side effects of medical treatment and surgery can also affect the patient’s ability to 
live a normal life. There is no cure for IBD and the cause is unknown. During my work as a 
nurse with IBD patients I have observed that some patients turn to CAM as they seem to be 
attracted by the holistic approach, which they appear to miss in conventional care. However, 
education about and knowledge of CAM in the healthcare system appears to be poor. For 
example, many healthcare professionals (HCPs) are not aware that, according to the Medical 
Products Agency (MPA), they should treat approved herbal medicinal products in the same 
manner as conventional medicines. There is a growing need for education about CAM in 
Sweden. It is necessary to illuminate both IBD patients’ experiences of and HCPs attitude 
towards CAM in order to meet the needs and wishes of these patients.  
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2 BACKGROUND 
2.1 THEORETICAL FRAMEWORK 
The theoretical framework in this thesis comprises chronic disease and self-care.  
2.1.1 Chronic disease 
When living with a lifelong disease, one can be overwhelmed by feelings of powerlessness 
and of one’s social and personal identity being threatened. Worries about no longer being 
able to rely on one’s body or know what is happening to it are also common. The above can 
give rise to feelings of insecurity and disrupted identity [5]. Patients with chronic diseases 
make self-care decisions on a daily basis, are experts about their own life and thus responsible 
for managing their own conditions and solving health in partnership with HCPs [6] 
2.1.2 Self-care 
There are several definitions of self-care that emphasise disease prevention and changes in 
lifestyle behaviour. The terms “self-care”, “self-management” and “self-help” tend to be used 
interchangeably. Self-help, describe support and help provided by self-help groups, often 
supported by health care [7].Self-management can be defined as how patients take 
responsibility for their own behaviour and well-being in the long term. It concerns the 
individual’s ability to manage, while self-care refers to activities taken by individuals [8, 9]. 
Dorothea Orem defined self-care as:  
“The practice of activities that individuals initiate and perform on their own behalf in 
maintaining life, health and wellbeing” ( p 117) [10]  
Orem holds that a person is an active and free human being who is reflective of both her/his 
surroundings and her/himself, with the ability to express her/himself by means of symbols. A 
human being can achieve wellness through self-care. The culture and social group to which 
an individual belongs affect how self-care actions take place. Individuals have a great 
responsibility to develop good habits and thus promote health [10]. The most recent 
definition of self-care from the World Health Organization (WHO) 2009 is:  
“Self-care is the ability of individuals, families and communities to promote health, prevent 
disease, and maintain health and to cope with illness and disability with or without the 
support from health-care provider“[11]. 
According to existing definitions, many activities can be considered self-care. There are 
specific self-care activities for most conditions, which differ from one individual to another. 
Self-care in a chronic disease is of great value with beneficial effects on well-being [8]. 
Research has also demonstrated the benefits of a self-management programme in a 
heterogeneous group of chronic diseases, such as improved health behaviours, better health 
status and fewer hospitalizations [12].  
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2.2 INFLAMMATORY BOWEL DISEASES (IBD) 
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic relapsing inflammatory bowel 
diseases (IBD) of the gastrointestinal tract [13, 14]. CD can affect the whole gastrointestinal 
tract from mouth to anus, but the most common locations are the last part of the small 
intestine and the colon, while UC is only present in the colon [14-16]. In UC only the 
innermost lining of the colon is inflamed, while CD affects the entire thickness of the bowel 
wall. IBD is lifelong and to date there is no cure.  
2.2.1 Etiology and epidemiology  
IBD is often diagnosed before the age of 30 years. The peak age of onset is between 15 and 
30 years, although it can occur at any age [13]. The causes of IBD are not fully understood 
[16, 17] and the etiology is believed to be multifactorial [13, 16, 18]. Associated factors 
related are barrier dysfunction, gut microbiome immune dysregulation and genetic 
predisposition [13, 16, 19, 20]. There are also environmental risk factors, such as smoking, 
appendectomy, diet, infections, nonsteroidal anti-inflammatory drugs (NSAID) and 
antibiotics. However, findings related to these factors are inconsistent [21, 22]. The highest 
prevalence and incidence of IBD is in the western nations with peak incidence rates in 
Canada and Northern Europe [15, 23]. Asia has a lower prevalence, but research revealed that 
when an individual emigrate from a low-to a high-incidence country, the risk of developing 
IBD is the same as that of the population of the high-incidence country. Furthermore, first 
generation children of immigrants seem to have a higher incidence of IBD than first nation 
persons [24]. About one million people in the US suffer from IBD [25] and the incidence 
rates are 9-20 cases/100,000 inhabitants for CD and 10-20 cases/100,000 inhabitants for UC 
[26, 27].In the Nordic countries the incidence of CD is 5-8 cases/100,000 and of UC 12-14 
cases/100,000 [28]. In Sweden, about 61,200 individuals live with UC and CD and the 
prevalence increases with age [29].  
2.2.2 Symptoms and diagnosis 
UC and CD are characterised by similar symptoms and usually the course of both diseases 
comprises periods of increased activity (flare) alternating with periods without inflammation 
(remission) but inflammation is sometimes chronic and continuously active. The symptoms 
include diarrhoea, often with blood or mucus, abdominal pain, malabsorption, weight loss 
and fatigue [30, 31]. Patients with UC tend to have more pain in the lower left part of the 
abdomen as well as diarrhoea with blood while CD patients experience pain in the lower right 
part of the abdomen and less frequent bleeding [30]. About one third of IBD patients develop 
additional extra intestinal symptoms that involve organs other than the gastrointestinal tract, 
the most common occurring in the skin, mouth, joints, hepatobiliary tract and eyes [32]. IBD 
is diagnosed by medical anamnesis and physical examination in addition to other techniques, 
the most common of which is colon - ileoscopy with biopsies of the tissues, which are used to 
confirm the diagnosis. Colonoscopy is an endoscopic examination of the large bowel, often 
combined with endoscopy of the distal part of the small bowel, called ileo colonoscopy. As 
the small intestine is more difficult to investigate, sometime magnetic resonance imaging 
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(MRI) and small bowel endoscopy with special instruments are sometimes used to confirm 
the diagnosis. Additionally, capsule endoscopy can be employed to confirm CD in the small 
gut. The patient swallows a capsule containing a camera that takes images of the inner layer 
of the gastrointestinal tract, which are transmitted to a computer. Moreover, lab test on blood 
and stool are also performed [30].  
2.2.3 Treatment and care 
The complexity of medical treatment has increased, and the use of new biological therapies is 
escalating [33]. Corticosteroids are one of the most common therapies in IBD, but as they are 
associated with a high risk of side-effects, because of that one goal is to reduce the 
corticosteroid dose by replacing them with other medications such as aminosalicylates, 
thiopurines, methotrexate, antibiotics, tumour necrosis factor alpha inhibitor (TNF-α) and 
other biological treatments [34]. However, TNF-α is also associated with a risk of side-effects 
including non-Hodgkin’s lymphoma [35], serious infections [36] such as opportunistic 
infections [37] and neurological events [38]. Another goal of the treatment is to reduce the 
inflammatory activity and help maintain remission [30]. During recent years IBD care has 
changed from a medical to a bio-psychosocial model [39]. The development of European 
guidelines has contributed to this [40].  
Sometimes the medical treatment fails and surgical treatment is required. The risks involved 
in surgery for IBD patients have decreased over the past six decades [41]. Surgery is a 
complement to medical treatment and can prevent complications as well as improve quality 
of life [42, 43]. The reasons for surgery in UC are acute colitis resistant to the medical 
treatment, continuous chronic activity inflammation, dysplasia and/or cancer of the colon and 
reconstruction after a previous colectomy. Primary surgery for UC usually involves removal 
of the large intestine (colectomy), closure of the remaining part of the rectum and ileostomy. 
This is usually followed by reconstruction with an ileal pouch-anal anastomosis (IPAA), 
ileorectal anastomosis (IRA) or a permanent ileostomy [44]. The indications for surgery in 
CD include resection of the inflamed bowel and inadequate response to medical treatment as 
well as the need to correct complications caused by the disease such as stenosis and fistula. 
The surgery in CD is focused to save as much bowel as possible through limited resections 
and stricture plastic [45]. 
2.2.4 The role of the IBD nurse 
In 2011, the Nurses-European Crohn’s & Colitis Organisation (N-ECCO) agreed on the need 
for a consensus statement on the nurse’s role in IBD care, thus the first N-NECCO consensus 
statements on European nurses’ role in caring for patients with Crohn’s disease or ulcerative 
colitis were published in 2013 [40]. Specialist IBD nurses play an important role in the 
coordination and management of patient care and are often the first point of contact for IBD 
patients, but the patients also need support from a multidisciplinary team [46, 47]. IBD nurses 
also provide advice, counselling and support, resulting in better compliance. Their 
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interventions could lead to reduced costs for the health service due to fewer hospital 
admissions [48]. 
In Sweden the patient’s position in healthcare has been strengthened by a new law (SFS 
2014:821) that highlights the concept of person-centred care. In person-centred care the 
patient is considered a partner in the relationship with HCPs and plays a more active role in 
participation and decision-making [49, 50].It is important for HCPs to be aware that the 
patient’s perception of care may differ from their own [46]. Person-centred IBD care is 
essential for positive outcomes and should include clear long-term planning and goal setting 
by the patient and multidisciplinary team [51].  
2.3 COMPLEMENTARY AND ALTERNATIVE MEDICINE-CAM 
2.3.1 What is CAM? 
There are many terms for Complementary and Alternative Medicine (CAM), making the 
concept difficult to define. The definition can differ from one country to another. The World 
Health Organization (WHO) definition is one of the most commonly used:  
”CAM refer to a broad set of health care practices that are not part of that 
country’s own tradition and are not integrated into the dominant health care 
system. They are used interchangeably with traditional medicine in some 
countries.” [52] p. 15.  
There are also differences between complementary and alternative medicine. The latter refers 
to the use of CAM instead of conventional medicine, while the former implies utilizing both 
CAM and conventional medicine. There is also Traditional Medicine (TM), which has been 
practised for a very long time in many countries. The WHO definition of TM is: 
“the sum total of knowledge, skills and practices based on the theories, beliefs 
and experiences indigenous to different cultures, whether explicable or not, 
used in the maintenance of health as well as in prevention, diagnosis, 
improvement or treatment of physical and mental illness.” [52]p.15  
Integrative medicine is the development and integration of evidence based, systematically 
follow- ups and evaluated knowledge from various forms of TM/CAM. The National Center 
for Complementary and Alternative Medicine (NCCAM), which is part of the National 
Institute for Health (NIH) in the US, defines integrative medicine as follows: 
“It combines treatments from conventional medicine and TM/CAM for which 
there is some high-qualitative scientific evidence of safety and effectiveness” 
[53]. 
The NCCAM groups CAM into five domains [53]: 
Whole medical systems: Theories and practices such as homeopathic medicine, Traditional 
Chinese Medicine and Traditional Indian Ayurveda Medicine. 
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Mind-body interventions: Strengthen communication between the mind and body, for 
example meditation, prayer and healing. 
Biologically-based therapies: Substances found in nature, including dietary supplements and 
herbal products.  
Manipulative and body-based methods: Employs human touch to move or manipulate a 
specific part of the body, for example, chiropractic therapy and massage. 
Energy therapies: Use energy fields in the body to promote health and healing, for example 
qi gong, tai chi and magnet therapy. 
2.3.2 CAM in Sweden 
The popularity of CAM in Sweden is increasing and a research report on CAM use in the 
county of Stockholm revealed an increasing from 22 % to 49 % between 1980 and 2001 [54]. 
The Swedish Council for Working Life and Social research (FAS) has emphasized the 
importance of determining CAM use in Sweden and the great need for advanced research in 
this area [55]. CAM is generally not provided within the Swedish healthcare system [56] and 
HCPs are not permitted to prescribe CAM treatments, except the herbal medicinal products 
approved by the MPA [57, 58]. The WHO has called for countries to take an integrative 
approach to CAM, which Sweden has not adopted, in contrast to several other countries 
including Norway, the UK, Germany and Australia. Although the WHO also states that 
access to CAM is a human right [59], there is no national CAM policy in Sweden and CAM 
is not officially approved in healthcare or within the education system, thus policy 
development is essential [60].  
2.3.3 CAM/TM internationally 
The interest in CAM among HCPs is high [61]. CAM use is increasing in the Western 
industrialized countries; in the US 42 % of the population use CAM, in Australia 48%, 
Canada 70 % and France 75 % [59]. However, many countries are struggling with questions 
concerning safety, quality, efficacy and research in this area [59]. The WHO is working 
towards the safe use of TM/CAM treatment through regulation, promotion of research and 
appropriate integration of TM/CAM products in the national health system. The organization 
has also recommended that member states should create a knowledge base, formulate 
national policies and strengthen their efforts in the areas of quality, safety and efficacy of 
TM/CAM [52]. The CAMbrella project was a European research network that developed a 
research strategy for CAM between 2010 and 2012. The research strategy covered six areas 
and identified important knowledge gaps [62]. The six areas are:  
 CAM prevalence  
 Needs and attitudes of citizens and providers 
 CAM safety 
 Comparative effectiveness research 
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 Effects of context and meaning 
 Models of CAM integration 
The results of the CAMbrella project indicated that there is a high demand for CAM in 
Europe but that regulation and education vary. With the exception of Norway, the UK and 
Switzerland, European countries have not examined the healthcare field in a thorough manner. 
CAMbrella recommends that a centre should be established in Europe in order to promote 
knowledge, research and development about CAM [63]. 
2.3.4 CAM and IBD 
Evidence of CAM use in IBD is rare and randomized controlled trials (RCTs) are necessary. 
Nevertheless, some evidence of CAM treatment in IBD exists [64]. Probiotics are live 
microbial dietary supplements and most data on their efficacy in IBD concern UC. VSL#3, a 
mix of four different probiotics, has been found to increase the clinical response and 
remission rate in mild to moderate UC [65, 66] and was effective in the prevention of 
pouchitis [67]. Ayurveda is the traditional Indian healing culture and has been practised for 
3000-4000 years. In Ayurveda health is based on the balance between food intake, physical 
activity and nature. Ayurveda medications are sold as dietary supplements and in a survey, it 
was found that several contain toxic metals, such as mercury and arsenic [68]. About 200 
different plants are used to treat various chronic diseases, some of which have an anti-
inflammatory effect [69], but there is no evidence of their effectiveness in IBD [64]. 
Traditional Chinese Medicine (TCM) is a combination of individualized herbal treatment and 
acupuncture but is mainly associated with the latter. There are few RCT studies of 
acupuncture in IBD, although, in two studies, one of CD and the other of UC, the Health 
Related Quality of Life (HRQOL) and disease activity scores improved markedly [70, 71]. 
Wormwood [72, 73], Aloe vera gel [74], wheat grass juice [75] and Bilberry [76] are other 
CAM methods tested for IBD, but controlled trials are still lacking [64]. Mind and body 
therapies are also CAM methods that have been studied in IBD. A Cochrane analysis of 21 
studies of a psychological intervention comprising relaxation techniques, patient education 
and psychotherapy revealed that psychotherapy had no effect on disease activity, HRQOL or 
emotional status [77]. On the other hand, hypnotherapy seemed to reduce stress and 
inflammatory reaction in IBD patients, leading to improved HRQOL, steroid- sparing effects 
and a reduction of the relapse rate [78-82].  
Patients with chronic diseases in general use CAM [83-85] as do patients with IBD [86-88]. 
The prevalence of CAM use in IBD patients over the last 20 years varied from 21% -74 % 
(Table 1).  
 
 
 
 
7 
 Effects of context and meaning 
 Models of CAM integration 
The results of the CAMbrella project indicated that there is a high demand for CAM in 
Europe but that regulation and education vary. With the exception of Norway, the UK and 
Switzerland, European countries have not examined the healthcare field in a thorough manner. 
CAMbrella recommends that a centre should be established in Europe in order to promote 
knowledge, research and development about CAM [63]. 
2.3.4 CAM and IBD 
Evidence of CAM use in IBD is rare and randomized controlled trials (RCTs) are necessary. 
Nevertheless, some evidence of CAM treatment in IBD exists [64]. Probiotics are live 
microbial dietary supplements and most data on their efficacy in IBD concern UC. VSL#3, a 
mix of four different probiotics, has been found to increase the clinical response and 
remission rate in mild to moderate UC [65, 66] and was effective in the prevention of 
pouchitis [67]. Ayurveda is the traditional Indian healing culture and has been practised for 
3000-4000 years. In Ayurveda health is based on the balance between food intake, physical 
activity and nature. Ayurveda medications are sold as dietary supplements and in a survey, it 
was found that several contain toxic metals, such as mercury and arsenic [68]. About 200 
different plants are used to treat various chronic diseases, some of which have an anti-
inflammatory effect [69], but there is no evidence of their effectiveness in IBD [64]. 
Traditional Chinese Medicine (TCM) is a combination of individualized herbal treatment and 
acupuncture but is mainly associated with the latter. There are few RCT studies of 
acupuncture in IBD, although, in two studies, one of CD and the other of UC, the Health 
Related Quality of Life (HRQOL) and disease activity scores improved markedly [70, 71]. 
Wormwood [72, 73], Aloe vera gel [74], wheat grass juice [75] and Bilberry [76] are other 
CAM methods tested for IBD, but controlled trials are still lacking [64]. Mind and body 
therapies are also CAM methods that have been studied in IBD. A Cochrane analysis of 21 
studies of a psychological intervention comprising relaxation techniques, patient education 
and psychotherapy revealed that psychotherapy had no effect on disease activity, HRQOL or 
emotional status [77]. On the other hand, hypnotherapy seemed to reduce stress and 
inflammatory reaction in IBD patients, leading to improved HRQOL, steroid- sparing effects 
and a reduction of the relapse rate [78-82].  
Patients with chronic diseases in general use CAM [83-85] as do patients with IBD [86-88]. 
The prevalence of CAM use in IBD patients over the last 20 years varied from 21% -74 % 
(Table 1).  
 
 
 
 
8 
 
 
Table 1 Prevalence of CAM use in patients with IBD 
Author  Year N Country CAM use When was 
CAM used? 
Verhoef et al. [89] 1990 395 Canada 27 % Current or past 
Hilsden et al. [90] 1998 263 Canada 51 % Last 2 years 
Hilsden et al. [91] 1999 263 International 46 % Last 2 years 
Rawsthorne et al. [92] 1999 289 US/Canada/Sweden
/Ireland 
51 % Current or past 
Langmead et al. [93] 2002 239 UK 26 % Current 
Hilsden et al. [94] 2003 2828 Canada 47 % Current or past 
Burgmann et al. [95] 2004 150 Canada 60 % Current or past 
Kong et al. [96] 2005 311 UK 50 % Current or past 
Langhorst et al. [97]  2005 671 Germany 51 % Current or past 
Bensoussan et al. [98] 2006 325 France 21 % Current or past 
D´Inca et al. [99] 2007 552 Italy 28 % Current or past 
Bertomoro et al. [100] 2010 2011 Italy 24 % Current or past 
Lakatos et al. [101] 2010 655 Hungary 31 % Current or past 
Weizman et al. [102] 2011 380 Canada 56 % Current or past 
Fernandez et al. [88] 2012 705 Spain 23 % Current or past 
Opheim et al. [103] 2012 430 Norway 49 % Last 12 
months 
Rawsthorne et al. [87] 2012 309 Canada 74 % Last 4-5 years 
Koning et al. [86] 2013 1291 New Zeeland 44 % Last 12 
months 
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D´Inca et al. [99] 2007 552 Italy 28 % Current or past 
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Lakatos et al. [101] 2010 655 Hungary 31 % Current or past 
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Koning et al. [86] 2013 1291 New Zeeland 44 % Last 12 
months 
9 
 
There are methodological limitations in prevalence studies of CAM in IBD, which makes 
comparisons of the prevalence in various countries problematic. One difficulty is that 
researcher use different definitions of CAM. For example, Burgmann et al. [95] include 
prayer and exercise in their CAM definition, while not all studies specify whether CAM 
was used for IBD or other health problems. In order to address that kind of problems, a 
group of international researchers have developed the International Questionnaire to 
Measure Use of Complementary and Alternative Medicine (I-CAM-Q) [104] which may 
contribute to comparable data from different countries for the epidemiology of CAM. IBD 
patients may turn to CAM because of poor quality of life [93], lack of efficacy of 
conventional IBD therapy [102], side-effects of steroid treatment [97], stress and the wish for 
a holistic approach or to gain greater control over the disease [105]. It is important to be 
aware that CAM use in IBD patients may be associated with non-adherence of conventional 
medicine [101], while other predictors are female gender [86, 87], younger age [86, 101, 
106], high educational level [86, 103], higher disease activity [88, 106] and psychological 
distress [93]. 
2.4 HEALTH-RELATED QUALITY OF LIFE (HRQOL) 
2.4.1 QOL and HRQOL 
Quality of life (QOL) is a broad and complex measure of the individual’s own evaluation of 
her/his physical, mental and social well-being. It also involves the perception of her/his 
position in life in the context of prevailing culture, norms and value systems in which she/he 
lives as well as her/his goals, expectations, standard, concerns, objectives, expectations, 
values and interests [107]. QOL can mean different things to different people and takes on 
different meanings according to the area of application [108, 109]. 
In 2006 the US Food and Drug Administration introduced the concept of Patient-Reported 
Outcome Measures (PROM) [110] , which provides information from the patients about their 
experience of illness and health after treatment or other interventions and includes HRQOL as 
a measure of physical, mental and social well-being. Validated HRQOL questionnaires can 
be both disease-specific and generic. Generic questionnaires allow comparisons between 
different diseases and patient groups [111, 112], whereas disease-specific questionnaires 
capture important aspects of a particular disease or patient population [113] . 
2.4.2 HRQOL and IBD 
There are several disease-specific instruments available for IBD [114]. The chronic nature 
and unpredictable course of IBD in addition to the fact that the peak age of onset is 15-30 
years lead to impaired HRQOL [1-4]. In a large European survey (n=5,576) as many as 76% 
of the IBD patients reported that symptoms affected their ability to enjoy leisure activities and 
70 % felt that symptoms affected their ability to perform at work [4]. The strongest predictors 
of HRQOL impairment were disease activity [1, 3, 115], stress, anxiety depression [3, 116] 
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and fatigue [2, 117]. HRQOL is not only influenced by disease activity and its medical 
management but also by insufficient efficacy and the side effects of medical treatment [118, 
119]. Corticosteroids are one of the most common forms of treatments in IBD and can lead to 
a number of side effects such as osteoporosis, osteonecrosis, cataracts, glaucoma, striae, 
diabetes mellitus, hypertension and psychological stress [120, 121]. About two-thirds of IBD 
patients will receive corticosteroid treatment within the first ten years and one third will be 
exposed to corticosteroids within one year of diagnosis. Heavy corticosteroid treatment 
during the first year of IBD is a strong predictor of surgery [34]. Immunomodulating 
treatment with tumour necrosis factor alpha inhibitor can cause serious side effects such as 
opportunistic infections [37], peripheral neuropathy as well as central nervous system and/or 
spinal cord demyelination [38].  
2.4.3 Worries and concerns 
Many IBD patients suffer from psychological distress and disease related worries can affect 
HRQOL in IBD patients. The highest rated worries are undergoing surgery and having an 
ostomy [122, 123]. Factors that seem to increase worry in CD patients are active disease, 
female gender and high body mass index (BMI) [122] and in UC ongoing relapse [123, 124]. 
Women with IBD report more intense concerns than men [125, 126] and, in addition, 
depression and coping are predictors of disease related concerns in IBD [126] as well as 
referral to a psychiatrist for counselling [127].  
2.4.4 Stress and IBD 
Psychological disorders in IBD are more frequent than in the general population [128, 129] 
and psychological stress is one of them. It is difficult to define stress, because the experience 
of stress may differ for each individual and can be both negative and positive [130]. Negative 
stress could be seen as a threat that starts a reaction in the brain, triggering the body’s stress 
response [131]. No study has found that stress is a cause of IBD [132] but it can be 
immunosuppressive [131] and affect disease activity and risk of relapse [133-135]. The way 
IBD patients deal with stress can affect their HRQOL [136]. Common coping strategies for 
stress in IBD are emotion focused [116], optimistic, self-reliant and confronted [137]. 
2.5 ENCOUNTERS IN HEALTHCARE 
2.5.1 Positive and negative encounters 
Healthcare encounters can be both positive and negative. In negative encounters the patients 
experience that HCPs treat them in a disrespectful and unhelpful manner. It has been revealed 
that patients find them rude, aggressive or arrogant due to being ignored, lack of empathy and 
that their personal integrity is not respected [138]. Positive encounters are person-centred, 
characterised by a perception of the HCPs’ sensitivity and empathy, during which the patient 
is given the opportunity to ask questions and is allowed to express her/his feelings 
[139].Communication barriers between physicians and IBD patients regarding CAM have 
been identified [98, 140]. Few physicians routinely initiated discussions about CAM with 
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patients, the reason for which could be lack of time, discomfort with and lack of knowledge 
about CAM on the part of the physician [140, 141]. IBD patients want to discuss CAM with 
physicians and would like open communication including information and support [142]. 
Some IBD patients were unwilling to speak openly about their CAM use, which may be due 
to the quality of the patient-physician relationship, failure of the physician to ask about it and 
fear of a negative respond from the physician [98, 140]. The IBD patients had the same 
experience of poor communication when it came to HRQOL and reported that physicians did 
not ask about the impact of the symptoms on their HRQOL [4]. This indicates a desire for 
emphasis on the personal context and not just focusing on the disease [142] 
2.5.2 Interview extracts 
The following text is an example of a young woman’s experience of a negative and a positive 
healthcare encounter. 
Gosh, we didn’t know what Crohn’s disease was. We had never heard of it and 
not many people had it. Then he sits down, and firstly he doesn’t manage to 
make eye contact, he wasn’t that kind of person. He didn’t like looking people 
in the eyes when talking to them. So he was always looking somewhere else. 
And he starts… the worst possible scenario. Immediately ‟ then we will remove 
the intestines, we put a bag on the stomach, then we do this and that etc. And 
this is more or less what the rest of your life will be like and you shouldn’t think 
that it will be any better.” 
As cold as ice and it was horrible, completely insane. And then just ‟ The 
nurses will be here if you need anything.” Then he gets up and leaves. I 
remember that mum and I just looked at each other and cried and cried and 
cried, until a nurse came into the room to check how we were. She found us 
crying and asking ‟ What is this? We don’t understand a thing, what kind of 
disease is this?” 
After a lot of ifs and buts I was moved to the adult ward. I was very ill with a 
high temperature, I had developed fistulas. Just beside the anus. At that time I 
had abscesses there that had to be drained, on two or three occasions, and the 
operations were not any fun, that’s for sure. Especially when you run to the loo 
20 times per day and you have to keep the area clean because you have recently 
been operated on. It really was hell. I was very very ill. I was admitted to the 
adult ward and encountered a new doctor and for me it was like the gates of 
heaven opened when I met him because this was a human being compared to 
the machine I had had to deal with before. The first thing he did was to go to 
me and give me a hug. And I thought ‟ What’s this?”. He dared touch me. He 
looked at me and mum and said ‟ I will help you, just relax and I will take care 
of you.”  
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It was so good to be told something like that at last, because all I had heard 
was ‟ you have to get used to it, this is your life, it’s what you must get used 
to!” 
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3 AIM 
The overall aim of this thesis was to investigate the use of CAM in patients with IBD and to 
explore attitudes to and experiences of CAM in patients with IBD and in HCPs. A further aim 
was to investigate IBD patient’s worries and disease related concerns in relation to CAM use. 
Specific aims: 
Study I. To identify the extent of and reason for CAM use in patients with IBD in 
Sweden, as well as the types of CAM, perceived effects compared with a 
control group. 
 
Study II. To explore IBD professionals’ attitudes to and experience of CAM. 
 
Study III. To describe experiences of CAM in the healthcare context reported by patients 
with IBD. 
 
Study IV. To explore the correlation between disease related concerns and CAM use in 
IBD patients. 
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4 ETHICAL CONSIDERATIONS 
Ethical approval for all studies was obtained from the Regional Ethical Review Board in 
Stockholm with reference numbers: 2008/4:6, 2009/852-32. All studies included in the thesis 
were conducted in accordance with the ethical principles for medical research involving 
human subjects contained in the World Medical Association Declaration of Helsinki, a 
central research ethics guideline. While not legally binding, it has nevertheless had a major 
impact on national legislation. One of the basic points of the declaration is that care should 
always come before scientific interests [143].  
All participants were provided with information about the study before being asked to 
provide informed consent. They were assured of confidentiality, for their personal 
information and that individuals would not be identified, that participation was voluntary and 
that they could withdraw at any time.  
In studies I and IV each patient received a questionnaire, which was numbered to ensure 
confidentiality. The code for each patient’s identity was kept in a safe place separately from 
the completed questionnaires. 
In studies II and III the researchers endeavoured to ensure that the methodology and findings 
facilitate for discussion and peer review. 
In all four studies the researchers did their utmost to protect the participants from distress, 
indignity, physical discomfort, personal embarrassment and psychological or other harm.   
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5 METHODS AND PATIENTS 
Different designs and methods were used depending on the aim of the study. 
Table 2. Overview of designs and methods  
Study Design Data collection 
method 
No. of 
participants 
Method of analysis 
I Quantitative cross 
sectional multi-
centre controlled  
Study specific 
questionnaire 
648 Fishers exact test, 
Mantel-Haenszel Chi 
square, Mann-Whitney 
U-test, Bivariate 
logistics regression 
II Descriptive 
qualitative 
Semi-structured 
interviews 
16 Manifest content 
analysis 
III Descriptive 
qualitative 
Semi-structured 
interviews 
15 Manifest/latent content 
analysis   
IV Mixed methods, 
quantitative cross 
sectional multi-
centre and 
descriptive 
qualitative  
Study specific 
questionnaire, 
RFIPC 
questionnaire and 
one open ended 
question 
 
645 Mann-Whitney test, 
Chi-2 test, Hierarchical 
clustering and 
Manifest/latent content 
analysis 
 
5.1.1 Study design 
In study I, a quantitative cross sectional controlled design was used with a study specific 
questionnaire. 
In studies II and III, a descriptive qualitative design with interviews was employed. The 
interviews were analysed by means of content analysis.  
In study IV, a mixed methods approach with quantitative cross sectional design and a 
qualitative questionnaire was used. 
5.1.2 Participants 
In study I, 854 patients with IBD from 12 different hospitals in Sweden were invited to 
participate of which 648 were included, given a respons rate of 76%. The patients came from 
both rural and urban areas. Data were collected by means of a study-specific questionnaire. A 
control group comprising general population was recruited through a postal survey to persons 
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and matched for age, gender, urban, rural and geographic location. The controls were selected 
from the Statens Personadressregister (SPAR), which includes all persons registered as 
resident in Sweden. The data collection in study I and IV started in August 2008 and ended in 
June 2009. 
In study II all requested participants agreed to take part in the study. The participants were 
16 nurses and physicians aged between 26 and 70 years old, who had worked with IBD 
patients for 1-42 years. They were recruited from four IBD clinics in two metropolitan areas. 
Purposeful sampling was used to obtain as much variation as possible in terms of experience 
and to achieve insight into IBD professionals’ attitudes to and experience of CAM. The 
variables on which the purposeful sampling was based were profession, gender, age and years 
in IBD care. The interviews were performed from April to October 2009.  
In study III the participants comprised 15 patients with IBD, eight with CD and seven with 
UC. The nine women and six men were recruited from two out-patient IBD clinics in one 
urban area of Sweden and ranged in age from 20-80 years (mean 45 years), with a disease 
duration of 2-34 years. All those invited to participate in the study accepted. Purposeful 
sampling based on the variables; diagnosis, gender, age and disease duration was employed 
to achieve as much variation as possible in terms of experience as well as insight into the 
phenomenon of CAM from the perspective of patients with IBD. The interviews took place 
from November 2011 to October 2012.  
Study IV had the same population as study I. In total, 854 patients with IBD from 12 IBD 
clinics in Sweden were invited to participate. Of these, 163 did not respond, 41 declined and 
5 were excluded due to incomplete questionnaires, thus 645 patients were included (response 
rate 76 %), of whom 317 had CD, 323 UC and 5 indeterminate colitis. Their mean age was 
43 years (18-89).  
5.1.3 Data collection 
In study I the patients were approached at 12 IBD clinics by an IBD nurse or physician who 
provided oral and written information about the study. If the patients agreed to participate 
they filled out the questionnaires either at the clinic or brought them home together with a 
stamped addressed reply envelope. At two of the centres the questionnaires were sent by post 
to participants. Two reminders were made by letter or telephone. The completed 
questionnaires were considered as informed consent. 
Demographic data such as age, gender, marital status, employment status, annual income and 
urban or rural residence and lifestyle habits were collected by the self-administered study 
specific questionnaire. On a list of 24 different CAM methods the participants were asked to 
indicate type and frequency of CAM use, reason for use, perceived effects of the CAM and 
whether their physician was informed about it. There was a space for noting “others” if the 
CAM used was not listed. Further questions included type of inflammatory disease (Crohn’s 
disease, ulcerative colitis, indeterminate colitis), current symptoms, year of diagnosis, 
conventional medication and perceived side effects 
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In study II nurses and physicians were contacted directly at the IBD clinics. Sixteen HCPs 
were recruited in accordance with the sampling framework (15-20 persons). All those invited 
agreed to participate. The interviews were conducted using a semi-structured interview guide 
with open-ended questions to fulfil the aim of the study [39]. Participants were invited to talk 
about their attitudes to and experience of CAM from their own perspective. No definition of 
CAM was given before the interviews. Probing questions were added during the interview 
(What do you mean? Could you explain?) A test interview was performed to assess the 
validity of the interview guide [39]. An audit trial of this interview was conducted by an 
external research group, which confirmed credibility. The first author (AL), who has 15 
years’ of experience as an IBD nurse, performed all interviews with the exception of two, 
which were conducted by the last author (LO) to ensure credibility and avoid bias [40]. The 
interviews, each of which lasted from 15-50 minutes, were conducted in a quiet private room 
at the participant’s IBD clinic. Before the interview the participants gave their informed 
consent.  
In study III the patients were approached from two out-patient IBD clinics and all those 
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were added in the same way as in study II. The interviewes lasted from 15-50 minutes. 
Study IV had the same data collection as study I. The patients were approached at their IBD 
clinic by a nurse or physician who provided oral and written information about the study. If 
the patients agreed to participate they filled out the questionnaires either at the clinic or 
brought them home together with a stamped addressed reply envelope. At two of the centres 
the questionnaires were sent by post to participants. Two reminders were made by letter or 
telephone. The completed questionnaires were considered as informed consent. Data on 
CAM use were derived from the study specific questionnaire. Data on patients worries and 
concerns were collected by the RFIPC which is a self-administered questionnaire for IBD 
patients [144, 145]. The RFIPC comprise 25 items, all of which begin with “Because of your 
condition how concerned are you about..?”. Each item is rated from 0-100 (0=Not at all, 
100=A great deal) on a visual analogue scale. A total score (sum score) is calculated as the 
mean of the 25 items. The RFIPC has been validated in Sweden and found to be reliable for 
both UC and CD patients [122, 146]. It was supplemented by an open ended question with a 
request for additional concerns. 
5.1.4 Data analysis 
In study I, groups were compared by means of Fisher’s exact test for dichotomous variables, 
the Mantel-Haenszel Chi Square tests for ordered categorical variables and the Mann-
Whitney U-test for continuous variables. Bivariate logistic regression was performed to 
predict the use of CAM. P-values < 0.05 were considered to indicate significant relationship. 
The IBM SPSS 22 Statistics software was used. 
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In study II, qualitative content analysis was employed. This is a research technique for 
analysing relatively unstructured data in order to arrive at replicable and valid conclusions 
from texts in their context [147, 148]. Krippendorff’s manifest qualitative content analysis 
method was applied, as it is appropriate for analysing text that focuses on communication and 
experiences [148]. A core feature of qualitative content analysis is the development of 
categories on the basis of similarities and differences at various logical levels. The interviews 
were recorded and transcribed verbatim. In the first step, the authors read the entire text 
several times in order to become familiar and gain a sense of the whole. Two domains were 
recognized: description of attitudes and description of experiences. In the next step, meaning 
units corresponding to the two domains were extracted and coded. Sentences and phrases 
containing information relevant to the aim were understood as meaning units. Each meaning 
unit was condensed, labelled, organised into groups and coded according to domain. This was 
followed by classifying and abstracting the meaning units into sub-categories and categories 
to highlight the content. During the analysis efforts were made to remain close to the 
interview text. Sub-categories and categories were identified by moving back and forth 
between categories, meaning units, domains and text. Data were analysed by the researchers 
and the outcomes discussed to ensure reliability. Disagreements were debated until consensus 
was reached. The researchers jointly discussed the validity to ensure that the sub-categories 
and categories were mutually exclusive and exhaustive. 
In study III, the qualitative content analysis method inspired by Krippendorff was employed 
[148] and the transcripts analysed by manifest and latent content analysis. NVivo 10 
qualitative software [149] was used for coding and analysis. The authors extracted, coded and 
grouped meaning units that corresponded to the aim of the study into sub-categories, 
categories and the theme. For the purpose of strengthening credibility, the analysis was 
conducted independently by all the authors, after which they discussed and reached 
consensus about the findings. 
In study IV, a mixed methods approach was used with both quantitative and qualitative 
methods. Quantitative data were analysed by means of the statistical analysis system R, 
version 3.1.0 [150]. The Mann-Whitney test was employed to assess differences between 
CAM users and non-CAM users as well as between continuous variables, e.g. age, disease 
duration and RFIPC. The Chi-2 test was applied to evaluate the difference between 
categorical variables, e.g. gender and disease. Hierarchical clustering was employed to 
identify groups with a high total RFIPC score. Statistical significance was set at p< 0.05. 
The qualitative data were analysed by qualitative content analysis in accordance to 
Krippendorff [148]. The transcripts of the replies to the open ended question were analysed 
using manifest and latent content analysis. The former refers to the obvious meaning of the 
text while the latter comprises interpretive reading in order to capture the deep structural 
meaning [147]. One hundred and forty five participants (95 women and 50 men), 86 of whom 
used CAM, commented on the open ended question: “Is there anything more that concerns 
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you?” The replies provided data comprising the meaning units, which were grouped into sub-
categories, categories and a theme.  
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6 RESULTS 
6.1.1 CAM use in patients with IBD 
Study I 
In study I the aim was to identify the extent of CAM use in IBD patients in Sweden, the most 
frequently used types of CAM and the reason for use in comparison with a control group. A 
total of 854 IBD patients were invited to participate, of whom163 did not respond, 41 
declined and two were excluded due to incomplete questionnaires. The study population thus 
comprised 648 patients (response rate 76%). The questionnaire was sent as a postal survey to 
1420 persons to form the control group. Thirty-three questionnaires were returned due to 
unknown address and in one case the person had died. Two reminders were sent by ordinary 
post and 440 persons responded, giving a response rate of 32%.  
Socio-demographic and disease data 
Of the 648 patients with IBD included in the study 324 (50%) had UC, 319 (49.2%) had CD 
and 5 (0.8%) of the patients had indeterminate colitis. Mean disease duration was 13.3 years 
(range 1-56 years). The overall, mean age of the IBD patients was 42.7 years (range 13-89 
years). The individuals in the control group were significantly older than patients with IBD, 
mean age 45.9 years (p = 0.0004). In the IBD group 48.3% of the patients were female, and 
58.1% of the controls (p=0.002). Significantly more of the controls lived together compared 
with IBD patients (p=0.004). IBD patients lived significantly more often in urban areas 
(p=0.001) compared to controls. Normal diet was significantly more common among controls 
compared to IBD patients (p=<0.0001). Differences between IBD patients and controls were 
adjusted for when comparing CAM use between groups. Level of education was similar in 
IBD patients and control group, 43% of the IBD patients had higher education and 45.9% of 
the controls, showing no statistically significant difference. Likewise there were no 
differences between IBD patients and controls concerning occupation. Twenty-eight per cent 
of the IBD patients were active tobacco users, 13.6 % of them smoked and 14.8% used other 
tobacco, e.g. snuff smokers. Current alcohol use was significantly higher in the control group 
(83.8%) compared with IBD patients (75.8%) (p=0.005). No other significant differences 
were observed between IBD and controls. 
Conventional medication, adverse effects  
Five hundred and eighty two (90.8%) of the patients with IBD reported that they had been 
prescribed medication for IBD and 43% reported the experience of an adverse event from this 
conventional medicine. 
 
UC vs CD 
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A significantly higher proportion of patients with UC were working (71.2%) compared to 
patients with CD (62.7%) (p=0.03), and the CD patients had a higher percentage of sick leave 
(17.2%) compared to patients with UC (7.4%). The smoking rate was higher among patients 
with CD (16.8%) than among those with UC (10.4%) but this was not statistically significant. 
No other significant differences were observed between UC and CD patients. 
CAM use 
Patients with IBD and controls had tried various kinds of CAM, see Table 3. A total of 48.3% 
of the IBD patients had availed of some form of CAM during the past year compared with 
53.5% of the control group, which revealed no statistically significant difference. However, 
when adjusted for age, gender, residence and diet, a statistically significant difference was 
found (p=0.02). The most common CAM in IBD patients was massage, which was used by 
21.3% compared with 31.4% of the controls (adjusted p=0.0003). The second most common 
CAM was herbal remedies, taken by 18.7% of the IBD patients compared with 22.3% of the 
controls (adjusted p=0.02). The IBD patients employed CAM on their own initiative. They 
obtained information from friends and relatives, the media, Internet and literature as well as 
being referred to CAM practitioners or recommended CAM by their HCP. 
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Effect of CAM experienced by IBD patients 
Eighty-three per cent of the 313 IBD patients who had used any CAM during the past year 
perceived the CAM as a positive experience, whilst 14.4% of them had experienced negative 
effect(s) from the CAM treatment. Massage was used by 138 IBD patients, from which 
77.5% experienced this CAM as positive, i.e. relaxing, pain relief and well-being, and 5.8% 
experienced a negative effect; pain, unease or ill-being. Herbal remedies were used by 121 
IBD patients and 66.1% of those perceived a positive effect from this CAM, i.e. to improve 
disease symptoms and well-being but also a general improvement. There was no negative 
experience of relaxation. Yoga was experienced as to achieve well-being, relaxation, and 
improve mobility. IBD patients who used acupuncture experienced pain relief, well-being 
and improved disease symptoms. 
 
Table 3. Kind of CAM used by patients with IBD within the last year, comparison between groups. 
 
Kind of CAM used 
 
IBD, 
n=648 
n (%) 
UC,  
n=324 
n (%) 
CD,  
n=319 
n (%) 
Controls, 
n=440 
n (%) 
IBD vs 
Controls 
p-value 
Adjusted 
p-value * 
       
Any CAM   313 (48.3) 147 (45.5) 163 (51.1) 235 (53.5) NS 0.02 
       
Massage   138 (21.3) 58 (18.0)   79 (24.8) 138 (31.4) 0.0002 0.0003 
Herbal remedy 121 (18.7) 51 (15.8)   68 (21.3)   98 (22.3) NS 0.018 
Relaxation   68 (10.5) 29 (9.0)   38 (11.9)   51 (11.6) NS NS 
Yoga     52 (8.0) 30 (9.3)   22 (6.9)   42 (9.6) NS 0.06 
Acupuncture     49 (7.6) 21 (6.5)   26 (8.2)   39 (8.9) NS NS 
Counselling      47 (7.3) 24 (7.4)   22 (6.9)   27 (6.2) NS NS 
Chiropractic    35 (5.4) 16 (5.0)   19 (6.0)   25 (5.7) NS NS 
Meditation     31 (4.8) 14 (4.3)   17 (5.3)   21 (4.8) NS NS 
Naprapathy     24 (3.7) 15 (4.6)     8 (2.5)   29 (6.6) 0.04 0.005 
Religion     23 (3.6) 10 (3.1)   13 (4.1)   20 (4.6) NS NS 
Homeopathy    15 (2.3)   8 (2.5)     6 (1.9)     7 (1.6) NS NS 
Qi gong     13 (2.0)   6 (1.9)     7 (2.2)  15 (3.4) NS NS 
Dietary change   12 (1.9)   6 (1.9)     6 (1.9)    2 (0.5) NS NS 
Reflexology     11 (1.7)   4 (1.2)     5 (1.6)  15 (3.4) NS 0.02 
Self-helping group     9 (1.4)   8 (2.5)     1 (0.3)    1 (0.2) NS  
Acupressure       8 (1.2)   2 (0.6)     5 (1.6)    8 (1.8) NS NS 
Healing     7 (1.1)   3 (0.9)     4 (1.3)  14 (3.2) 0.02 0.002 
TCM     6 (0.9)   5 (1.5)     1 (0.3)    4 (0.9) NS NS 
Hypnosis      4 (0.6)   3 (0.9)     1 (0.3)    1 (0.2) NS  
Anthroposophy     3 (0.5)   1 (0.3)     2 (0.6)    5 (1.1) NS  
Shiatsu      3 (0.5)   1 (0.3)     1 (0.3)    5 (1.1) NS NS 
Aromatherapy       2 (0.3)   1 (0.3)     1 (0.3)    5 (1.1) NS NS 
Ayurveda        2 (0.3)   2 (0.6)     0 (0.0)    4 (0.9) NS  
Rosen Method Bodywork  
 
    1 (0.2)   0 (0.0)     1 (0.3)    2 (0.5) NS NS 
For categorical values n (%) are presented. For pairwise comparisons between groups, Fisher’s exact test was used for 
dichotomous variables. *Adjusted for age, gender, residence, diet using logistic regression TCM, Traditional Chinese Medicine 
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6.1.2 CAM use in IBD patients from the perspective of HCPs 
Study II 
In Study II the aim was to explore IBD professionals’ attitudes to and experience of CAM. 
All participants had experience of IBD patients who had used CAM in an attempt to achieve 
improvement and well-being. Attitudes to CAM were mainly positive, although a 
problematic aspect was lack of knowledge and evidence. Implementing CAM education in 
nursing and medical school would allow HCPs to gain an understanding of therapies widely 
used by patients with IBD. In clinical practice, a standard questionnaire about CAM would 
enable HCPs to better understand their patients’ wishes and current CAM use. 
Sixteen IBD professionals (seven physicians and nine nurses) were interviewed. Their mean 
age was 49 years (range 26–70), 11 were women and five were men. Their mean clinical 
experience in the IBD area was 20 years (range 1–42). The results are presented in two 
domains; Attitudes and Experiences, each of which generated four categories; Creating 
trust and a good relationship with the patient, Wishing for knowledge and understanding, 
Trust in CAM and Attitudes that constitute a barrier, each with two to six sub-categories. 
The sub-categories are strengthened by quotations from the participants. 
Attitudes 
Category I. Creating trust and a good relationship with the patient 
This category included three sub-categories; Strategies for the encounter with patients, 
Searching for information on the patients’ behalf and A positive attitude to CAM. 
The participants emphasised the importance of treating patients with respect when they told 
about their CAM use. They also stressed the importance of creating trust and a good 
relationship with patients as well as maintaining contact and assisting them in searching for 
information about CAM. Several expressed a positive attitude towards CAM in addition to 
curiosity about and an interest in different CAM methods. 
“You have to be very careful not to have a superior attitude towards the patient and not say 
that it’s nonsense and to stop taking it. That would be very dangerous and can ruin the 
relationship with the patient.” 
Category II. Wishing for knowledge and understanding 
This category generated the sub-categories; Willingness to learn about CAM, Searching for 
relevant education and Raising the level of awareness about and concretizing patients’ CAM 
use. 
It was clear that the participants wanted additional knowledge about CAM, stating that it 
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that they wanted factual and evidence based knowledge that they could communicate to their 
patients. 
“When considering our patients and their problems, it would be very interesting to learn 
more. “ 
Category III. Trust in CAM 
This category generated the sub-categories; Acceptance of CAM, CAM as a complement to 
conventional treatment, Untapped resource, The right time for CAM and Confidence in 
manual therapies. 
The level of acceptance of CAM varied among IBD professionals and became higher when 
CAM was used as a complement to conventional medication. CAM was considered an 
untapped resource that had a place within healthcare. Some participants were of the opinion 
that conventional healthcare was inadequate, arguing that CAM fulfilled a function from a 
psychological perspective. Others claimed that interest in CAM had increased in society and 
that it was the right time for it. Some expressed confidence in manual therapies, as they 
believed that touch could induce well-being in patients 
“I definitely believe in touch, if you feel taken care of, you will feel better.” 
Category IV. Attitudes that constitute a barrier 
This category generated the following sub-categories; Restrictive approach, Distanced view, 
No need of or interest in CAM, Personal definition of CAM and Reticence about CAM. 
Several participants had a distanced view of CAM, being uncertain about what attitude or 
approach to adopt and tried to remain neutral. Only a few were skeptical although many had a 
restrictive attitude to herbal remedies and over-the-counter products due to experiences of 
side-effects. These IBD professionals considered that CAM was unnecessary, in light of the 
number of effective medications available for IBD treatment. Few believed that CAM could 
help patients with IBD and only one participant expressed a specific interest in CAM. The 
IBD professionals found it difficult to define the concept of CAM and one claimed that the 
terms complementary and alternative were synonymous. The concept was regarded as diffuse 
and some were of the opinion that CAM is not provided in today’s healthcare system. 
“I’m a bit concerned about the risk involved in using CAM in place of traditional 
medication.”  
Experiences  
Category I. Motives for CAM use 
This category generated the sub-categories; Concern about side-effects of conventional 
medication, Patients’ wish to avoid conventional medication, Disease course, Interest, The 
influences from the surrounding environment and CAM provides a holistic perspective. 
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The participants reported that in many cases long-term disease, a complicated disease course 
and worries about the side-effects of conventional medication were the reasons why IBD 
patients tried CAM methods. They also perceived that patients with a chronic condition were 
more likely to try CAM to ensure that they had done everything possible in order to regain 
health. In their view, some of these patients were interested in CAM, which influenced them 
to start using it.  
“I think that a lot of them are very open, especially those who are ill as they try out all 
avenues in order to regain their health.” 
Some participants reported lacking the holistic perspective that takes account of patients’ 
perceptions and is a characteristic of CAM but missing in conventional healthcare. They 
considered that the surrounding environment such as the media and financial aspects 
influenced CAM use. Other factors perceived to influence CAM use were traditional and 
cultural differences. 
“CAM embodies much that has been lost in patient care today, namely care of the whole 
patient.” 
Category II. Perceiving patients’ quest for improvement and well-being 
This category generated the following sub-categories: the patient is searching, the patient 
believes in the efficacy of CAM and the patient informs about her/his CAM use. 
The IBD professionals perceived that many patients expressed a specific interest in and asked 
for CAM treatment. They believed that patients did everything in their power to regain health 
and would try CAM sooner or later. They also stated that patients were very interested in 
CAM, believed in its efficacy and frequently asked health professionals about it. The majority 
perceived the patients as honest in terms of informing them, although a few considered that 
the patients might have forgotten to mention their CAM use or believed that they were not 
truthful due to fear of being disparaged. Furthermore, they were of the opinion that patients 
had too much trust in CAM, believing it to be harmless and without side-effects. 
“Many patients believe that herbal remedies are something natural, not real medications, 
and good for the body and non-toxic, which I can understand.” 
Category III. Problematic aspects 
This category generated the sub-categories; Limited knowledge/education and Safety and 
efficacy. 
The IBD professionals found it difficult to obtain knowledge about CAM due to the large 
number of CAM methods and the fact that CAM is not included in their basic education. One 
participant was of the opinion that no CAM education was necessary. However, the majority 
reported that they lacked knowledge about CAM. CAM was perceived as a limited area and 
the participants would like impartial information about safety and data on efficacy. They 
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stressed the need for a system to control CAM methods and the importance of designing 
randomised control studies. One important aspect mentioned by several of the participants 
was that CAM methods must not interact with patients’ ordinary medication for treatment of 
an acute onset. 
“CAM must not interfere, interact with essential acute treatment or delay a treatment of an 
underlying or a diagnosed illness.” 
Category IV. Differing CAM experiences 
This category generated the following sub-categories; Personal experiences of CAM, 
Influence of patients’ narratives about CAM, Experiences of friends/relatives and 
Professional experiences of CAM. 
The participants had varying experiences of CAM. Many had a positive personal experience 
of manual therapies, others had relatives who had tried CAM, while a few had no personal 
experience of CAM. However, all were familiar with patients who had employed various 
CAM methods with both positive and negative outcomes. 
 “I have met many over the years who attended the anthroposophic clinic. “ 
6.1.3 CAM from IBD patients’ perspective 
Study III 
Study III focused IBD patients’ experiences of CAM in the context of healthcare. Our results 
revealed that the patients found it easier to discuss CAM with nurses than physicians and 
wished to be asked about CAM as a means of starting a dialogue. The patients perceived that 
HCPs were unwilling to discuss CAM, treated them in a disparaging manner and did not take 
them seriously.  
The analysis revealed the theme Knowledge and communication lead to participation in 
the area of CAM based on the following three categories; CAM use, Communication and 
Self-care in addition to fourteen sub-categories. The latter are strengthened by quotations 
from the interviews. 
Category I. CAM use 
This category consisted of the sub-categories: Changed dietary habits, Factors that influence 
CAM use, Experience of CAM, Trust in CAM, No need for CAM, Doubtful about CAM as 
well as Science and safety. 
Some of the participants considered changed dietary habits, such as excluding gluten, lactose, 
dairy products, sugar, flour, E-numbers, raw meat and reducing calorie intake, an important 
CAM. They reported an improvement in their IBD as a result of dietary changes but stated 
that they had received inadequate support from HCPs.  
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“I have been told that it doesn’t matter what you eat, which sounds quite absurd to someone 
who suffers from bowel disease.” 
The participants mentioned several reasons that influenced them to start using CAM, such as 
side effects or failure of conventional treatment. They were against the use of corticosteroids 
and perceived taking many conventional medications as traumatic, although they were 
prepared to try everything, in the hope that it would have a positive effect. 
“Anything that will make me better is OK” 
The majority of the participants had tried CAM in the form of dietary change in an effort to 
alleviate the disease. For example, they no longer consumed carbohydrates, sugar or products 
containing solanine, such as potatoes, paprika and tomatoes. They boiled Chinese herbs to 
make a tea and some tried Probiotics with varying results. Several found massage and yoga 
beneficial for alleviating IBD symptoms, reducing stress and increasing energy levels. 
“I don’t know if it was [probiotics] but I think so. It was really strong and I experienced a 
great difference at the beginning.” 
The participants trusted CAM, deeming it valuable and that it had a place in healthcare. Some 
of them experienced CAM as positive in that it reduced stress. However, others were 
ambivalent, sceptical and not interested in using CAM, while a few expressed doubt about 
herbal treatment. The participants would feel safer trying CAM if it was provided by the 
health services. However, they respected the fact that HCPs have to work with evidence-
based methods, stating that they would be positive about using CAM when research based 
evidence is available. 
“Then there are things that I haven’t tried, herbal medicines and such, I don’t trust them as 
much, because I have too little knowledge about them. My gut feeling is that there’s too much 
humbug in that area and a lot of desperation.” 
Category II. Communication 
This category comprised the following sub-categories: Perception of doctors’ and nurses’ 
attitude to CAM, Relationship with the doctor, Revealing CAM use and Wishing for a 
dialogue about CAM. 
According to the participants, doctors and nurses lacked knowledge and were reluctant to talk 
about CAM, leading to inadequate care. They reported receiving no support from the 
healthcare service regarding CAM use and that HCPs rarely discussed CAM.  
“HCPs don’t talk about CAM of their own accord.” 
Some mentioned not being taken seriously and treated in a disparaging manner when trying 
to discuss CAM. They were also critical with the dietary advice received and suggested that 
HCPs should discuss diet on a regular basis with patients suffering from IBD. The 
participants wished for a dialogue about CAM, as they were open to discussing it and wanted 
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to obtain support for CAM treatment. Some only told nurses about their CAM use, as they 
considered nurses to have a more relaxed attitude towards CAM and found it easier to discuss 
with them than with doctors. 
“But nurses are a bit more open to it [CAM]. It was easier to have a dialogue with them 
about it.” 
 
On the issue of whether to reveal their CAM use, some did while others did not. Reasons for 
the latter were feeling ashamed, being aware that their doctor did not believe in CAM, respect 
for the doctor and the fact that CAM is not a part of healthcare. They did not mention it 
unless asked about it by HCPs.  
“You feel ashamed, perhaps you have done something that is not quite OK or you don’t know 
what the doctor will think about it, maybe out of respect for the doctor.” 
Category III. Self-care 
This category comprised the following sub-categories: Making own choices, Living as 
normally as possible and Searching for and obtaining CAM knowledge. 
The participants considered that making one’s own choices, being allowed to have influence 
and doing something oneself were important, which was why some turned to CAM. 
“I think having an opportunity to influence one’s own situation makes people feel good. Take 
dietary change as an example, I think it makes a difference that you can sort of control it 
yourself.” 
They searched for and obtained CAM knowledge via the Internet when they needed it. Some 
talked to other patients in order to share experiences. 
“You try to talk to other patients to find out their experiences.” 
 6.1.4 CAM use and IBD patients’ health related concerns 
Study IV 
In study IV the aim was to explore the association between disease related concerns and 
CAM use in IBD patients. 
The quantitative results 
Relationship between the demographic data of CAM users and non-CAM users  
Statistically significant differences between CAM users and non-CAM users were found in 
relation to age (p=0.0002) and gender (p= 0.000), but there were no differences in terms of 
diagnosis, disease duration and symptoms.  
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Relationship between CAM use and disease-related concerns 
There was a statistically significant difference between CAM users and non-CAM users, the 
former exhibiting more concerns in 15 of the RFIPC items and having a higher total RFIPC 
score (p=0.003). The three highest rated concerns reported by patients using CAM were 
having an ostomy bag, loss of bowel control and reduced energy levels. 
Table 4 IBD patients’ RFIPC items and CAM use or non-use. The statistical significance was 
p< 0.05. 
 
 
Rank 
 CAM use 
(N=310) 
Mean (SD) 
Non CAM use 
 (N=326) 
Mean (SD) 
Total 
(N=637) 
Mean (SD) 
P-value 
1 Having an ostomy bag 51.4 (36.6) 48.0 (36.8) 49.7 (36.7) 0.25 
2 Loss of bowel control 49.3 (34.4) 41.8 (34.0) 45.5 (34.3) 0.006 
3 Energy level 47.3 (32.7) 38.5 (30.6) 42.9 (32.0) 0.001 
4 Having surgery 43.3 (34,0) 40.8 (33.7) 42.1 (33.7) 0.37 
5 Effects of medication 43.2 (30.4) 36.0 (30,0) 39.5 (30.3) 0.001 
6 Uncertain nature of my disease 42.4 (32.3) 35.2 (30.8) 38.8 (31.8) 0.003 
7 Being a burden on others 41.8 (34.4) 35.5 (32.6) 38.7 (33.6) 0.04 
8 Developing cancer 41.8 (32.7) 36.4 (31.9) 39.0 (32.4) 0.05 
9 Ability to achieve full potential 41.1 (32.3) 34.8 (30.9) 37.9 (31.8) 0.009 
10 Pain or suffering 36.9 (29.3) 30.0 (27.9) 33.5 (28.8) 0.002 
11 Dying early 36.5 (32.7) 33.0 (31.2) 34.7 (32.0) 0.23 
12 Producing unpleasant odors 35.0 (34.9) 32.0 (34.3) 33.5 (34.7) 0.21 
13 Feelings about my body 34.4 (31.0) 28.9 (28.8) 31.6 (30.0) 0.016 
14 Attractiveness 33.2 (29.8) 31.3 (31.3) 32.3 (30.6) 0.02 
15 Financial difficulties 33.2 (33.2) 25.3 (29.9) 29.2 (31.8) 0.004 
16 Having access to quality medical care 31.9 (32.1) 25.8 (29.2) 28.9 (30.9) 0.03 
17 Feeling out of control 31.8 (30.7) 26.7 (29.1) 29.3 (30.0) 0.02 
18 Loss of sexual drive 30.9 (31.7) 28.4 (31.3) 29.7 (31.6) 0.16 
19 Intimacy 29.8 (31.6) 26.4 (30.2) 28.2 (31.0) 0.08 
20 Passing the disease to others 28.9 (34.0) 21.0 (29.2) 24.8 (31.8) 0.007 
21 Feeling alone 29.6 (29.5) 27.2 (29.7) 28.4 (29.6) 0.19 
22 Ability to perform sexually 26.8 (29.0) 25.8 (29.7) 26.4 (29.4) 0.28 
23 Feeling "dirty" or "smelly" 25.4 (30.4) 20.9 (27.3) 23.2 (29.1) 0.07 
24 Ability to have children 22.8 (30.5) 15.4 (25.2) 19.0 (28.1) 0.006 
25 Being treated as different 21.4 (25.7) 16.7 (23.6) 19.0 (24.7) 0.003 
 RFIPC total sum score 35.6 (21.9) 30.5 (21.3) 33.0 (21.8) 0.004 
 
One patient did not respond to the question about CAM use and eight patients did not 
complete the RFIPC. Five patients with indeterminate colitis were excluded from the analysis 
and 60 patients did not state their IBD symptoms. 
 
Hierarchical clustering  
Some of the patients had a high RFIPC total score (n=118, mean 67), which means that they 
rated their concern strongly on all items. To identify this group of patients we employed 
hierarchical clustering analysis to detect responses with high disease related concern in all 25 
items. There is no exact answer as to how many groups are needed in a hierarchical clustering 
analysis. However, we used four groups developed through a dendrogram based on the 
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13 Feelings about my body 34.4 (31.0) 28.9 (28.8) 31.6 (30.0) 0.016 
14 Attractiveness 33.2 (29.8) 31.3 (31.3) 32.3 (30.6) 0.02 
15 Financial difficulties 33.2 (33.2) 25.3 (29.9) 29.2 (31.8) 0.004 
16 Having access to quality medical care 31.9 (32.1) 25.8 (29.2) 28.9 (30.9) 0.03 
17 Feeling out of control 31.8 (30.7) 26.7 (29.1) 29.3 (30.0) 0.02 
18 Loss of sexual drive 30.9 (31.7) 28.4 (31.3) 29.7 (31.6) 0.16 
19 Intimacy 29.8 (31.6) 26.4 (30.2) 28.2 (31.0) 0.08 
20 Passing the disease to others 28.9 (34.0) 21.0 (29.2) 24.8 (31.8) 0.007 
21 Feeling alone 29.6 (29.5) 27.2 (29.7) 28.4 (29.6) 0.19 
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One patient did not respond to the question about CAM use and eight patients did not 
complete the RFIPC. Five patients with indeterminate colitis were excluded from the analysis 
and 60 patients did not state their IBD symptoms. 
 
Hierarchical clustering  
Some of the patients had a high RFIPC total score (n=118, mean 67), which means that they 
rated their concern strongly on all items. To identify this group of patients we employed 
hierarchical clustering analysis to detect responses with high disease related concern in all 25 
items. There is no exact answer as to how many groups are needed in a hierarchical clustering 
analysis. However, we used four groups developed through a dendrogram based on the 
30 
 
Euclidean distance between the individuals in the material (n=637). To further test the 
differences in the characteristics of the four groups, they were compared in terms of age, 
gender, disease symptoms, disease duration and CAM use or non-CAM use. One of the 
groups (n= 118) had a total mean score of 67 for the RFIPC. Its characteristics were 62 % 
women and 61% CAM users with shorter disease duration (mean 12 years). 
Qualitative results 
The analysis of the open ended question with a request for additional disease related concerns 
revealed the theme: Inflammatory bowel disease affects the whole of everyday life based 
on three categories; Family and the self, Disease burden and Associated factors as well as 
sixteen sub-categories.  
The category Family and the self comprised the following sub-categories: Family members’ 
concern, Work, Stress caused by uncertainty, The future, Hereditary factors, Never 
experiencing health and Influence on everyday life 
Category I. Family and the self 
Some of the participants were concerned due to their family members worrying about them, 
how the disease impacted on the family and how the children were affected by having an ill 
parent. Some participants were worried about the children having to give extra consideration 
to the fact that one parent had a chronic disease. 
“How my children are affected by having an ill mother.” 
Work related concerns were expressed such as not being part of working life and fear of 
losing one’s job. Some of the participants worried about lost career opportunities and a small 
pension as well as finding it difficult to accept being unable to work as much as they wished. 
They also worried about not feeling useful, which led to depressed mood. Concerns about the 
future emerged in relation to work, their financial situation and the family as well as their 
children’s future and not finding a partner.   
“My future. How can anyone be strong enough to love me when I’m ill and with all the 
complications involved?” 
The participants were concerned about heredity and transferring the disease to their children. 
They also worried that the disease would have an effect on pregnancy. Several mentioned 
that their doctor had not given them any clear answers with regard to heredity and worried 
about the effect of medication on fertility. 
“I’m scared to death of transmitting the disease to future children, especially as my partner 
also suffers from ulcerative colitis.” 
They were concerned about the fact that IBD is chronic and about never experiencing health. 
IBD had a major impact on their life such as inability to take care of their children or being 
unable to go abroad. They perceived that the symptoms ruled their life, making it difficult to 
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lead a normal existence. The bowel symptoms appeared suddenly and unexpectedly, causing 
a stressful situation. One participant claimed that the disease had a negative impact on his 
attitude to adversity in general.  
“The fact that my stomach does not function puts me in a bad mood. I get annoyed and tetchy 
towards others because my bowels cause me trouble.” 
Category II. Disease burden 
The category Disease burden comprised the sub-categories: Unable to reach a toilet in time, 
Fatigue, Pain, Ostomy, Fear of complications and Diet. 
A concern expressed by the participants was the fear of being unable to reach a toilet in time 
and inability to control the bowel. This was especially pronounced when travelling by public 
transport, which sometimes made them choose not to leave their home.  
“Being unable to control the bowel and that it suddenly soils my pants when among people.” 
Fatigue was a concern, as experiencing that the body let them down was difficult. The fatigue 
was perceived as considerable, restricting their working life, social life and studies. 
“That my body lets me down so ruthlessly that it affects the entire everyday life of both myself 
and my family members.” 
The participants feared pain, a symptom perceived as becoming more severe with age. It was 
regarded as a vicious circle, where stress increased the pain and pain caused even more stress. 
A concern reported by the participants was fear of an ostomy. Some had previously had one 
and definitely did not want another, especially as they were concerned about deterioration in 
the quality of the bags. 
“My worst scenario is getting a stoma bag on my stomach. Should that happen it would feel 
as if life was over.” 
Major concerns were complications such as primary sclerosing colitis (PSC), fistulas, 
arthritis, osteoporosis, incontinence and cancer, the side effects of cortisone, Imurel and 
Remicade as well as the potential long-term bodily impact of various medications. 
“I’m afraid of side effects that won’t go away, such as fistulas and arthritis.” 
Another concern was diet, for example, being careful about food intake and fear of eating the 
wrong type of food. 
Category III. Associated factors 
The category Associated factors comprised the sub-categories: Financial worries, Healthcare 
encounters and experiences as well as Holistic perspective in conventional care. 
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The participants were concerned about their financial situation and found it difficult to deal 
with the Social Insurance Agency, as the sickness benefit application process was perceived 
as awkward and taking a long time. Another concern was the way in which they were 
encountered and their healthcare experiences. Some participants worried about not having 
access to a specialist physician, while several had lost confidence in physicians, expressing 
that they had not been encountered with respect. There was a fear of ending up in the wrong 
hospital as well as a wish to be treated by the same physician and having annual check-ups. 
Some were disappointed that research had not resulted in better treatment options and that too 
little effort was devoted to research. 
“That so many doctors who I encountered lacked empathy and did not take my questions and 
reflections seriously.” 
The participants were concerned about the absence of a holistic perspective in conventional 
care. One of them stated that physicians only focus on the strictly medical aspects as opposed 
to the whole human being. Some mentioned a lack of social workers in the care services as 
well as perceiving contact with them as something one did not talk about.  
“You can’t get psychological help in hospitals today as they don’t treat the whole human 
being.” 
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7 DISCUSSION  
7.1 METHODOLOGICAL CONSIDERATIONS 
A strength of this thesis is the use of both qualitative and quantitative methods. Qualitative 
research was previously criticized for being unscientific and subjective. However, in the past 
decade it has become an important mode of inquiry for social sciences [151]. A combination 
of quantitative and qualitative methods provides an expanded understanding of research 
problems compared to either approach alone and opens the way for synergy effects [152]. 
In Study I the strength was that it was a multicentre, controlled study with different 
geographic locations, which increases generalizability. The drop out in the control group was 
larger than in the IBD group, but no difference was found when the data were adjusted for in 
terms of CAM use. Another methodological issue was that two of the centres chose to post 
the questionnaires to the participants, resulting in fewer participants.  
Studies II, III and part of IV had a qualitative design. The qualitative research method 
allowed the participants to talk or write freely about CAM and their disease related concerns. 
The qualitative analysis revealed their experiences by means of their own words and 
statements. A methodological issue in qualitative research is the researchers’ pre-
understanding, which could affect objectivity. The first author (A L) has worked with IBD 
patients for 15 years, but was not involved in the care of the participants. To avoid bias all 
authors independently read and analysed the text, after which lack of agreement was 
discussed until consensus was achieved. Qualitative studies are often judged on the basis of 
trustworthiness, which concerns transferability, credibility, confirmability and dependability 
[153]. 
Transferability was ensured by the rich descriptions of the phenomenon, even in the shortest 
interview, which lasted for 15 minutes. The participants in studies II, III and IV all came from 
IBD care, i.e. the same context, which also enhances transferability.  
In study II credibility was strengthened by the selection of participants of different ages, 
gender, disease duration, a diagnosis of UC or CD and with various experiences of CAM use 
and in study III credibility was enhanced by the inclusion of participants of different ages, 
gender and professional IBD experience.  
Conformability implies that the researcher should remain objective. The first author (AL) 
who conducted the interviews in studies II and III is an IBD nurse who worked with such 
patients for 15 years. To prevent bias due to pre-understanding, all authors independently 
read and analysed the text, after which they discussed any disagreements until consensus was 
reached. However, the credibility of the researcher is of critical importance in qualitative 
studies. As the present authors’ pre-understanding ensured knowledge and comprehension of 
the context, it can be considered a strength. 
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Dependability was achieved by the researchers becoming familiar with the text and 
continuously returning to it to ensure that the emerging categories and sub-categories covered 
all relevant aspects. It was also enhanced by a description of the research design and analysis 
process.  
In Study IV a mixed methods approach was used. A combination of quantitative and 
qualitative methods provides an greater understanding of the research problems compared to 
either approach alone [152]. An additional strength was the multicentre design, with patients 
from 12 different geographic locations in Sweden, which increases generalizability. 
7.2 GENERAL DISCUSSION 
The four studies in this thesis highlight IBD patients’ CAM use and disease-related concerns 
associated with CAM in addition to the attitudes to and experiences of CAM on the part of 
IBD patients and HCPs.  
The main findings in this thesis were that CAM use is common among Swedish IBD patients, 
especially massage and herbal remedies. IBD patients found it easier to discuss CAM with 
nurses than with physicians. Furthermore, they wanted to be asked about their CAM use in 
order to start a dialogue but felt that HCPs treated them in a disparaging manner, which 
contradicted what the HCPs expressed. The HCPs emphasized the importance of treating 
patients with respect when they informed about their CAM use. In general, IBD patients who 
availed of CAM had more disease related concerns compared with those who did not use 
CAM and also reported that they missed a holistic approach in conventional healthcare. 
7.2.1 CAM and healthcare 
The result of study IV shows that in general, IBD patients who used CAM had more disease 
related concerns compared with non-users and expressed concerns about the absence of a 
holistic perspective in conventional care. This is supported by the result of study II, where the 
HCPs emphasized that one reason patients with IBD turned to CAM was the wish for a 
holistic approach. Thus it appears that something is lacking in conventional healthcare and 
we must start thinking about how we treat our patients in terms of involving and developing 
the whole person, both physically and psychologically. One barrier is the absence of a 
national CAM policy in Sweden. We need an integrative approach to CAM in line with the 
WHO recommendation that countries should formulate national policies and increase efforts 
in the areas of quality, safety and efficacy of CAM [60]. 
There is a lack of evidence about dietary interventions in IBD patients and dietary changes 
are not included in the WHO’s definition of CAM. However, almost all of the participants in 
study III expressed that dietary changes were/are an important part of CAM and were of the 
opinion that such changes may have been beneficial for them. They also stated that HCPs 
were not supportive when it came to implementing dietary changes. HCPs should be aware 
that dietary changes are essential for many IBD patients, which is in line with Zallot et al. 
[154] who found that as many as 58 % of their participants believed that food played a role in 
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relapse. It is important for HCPs to start a dialogue with patients about diet and studies of 
dietary changes in IBD are urgently required.  
7.2.2 Consequences for the patient  
The result of study I revealed that herbal remedies are a common form of CAM among IBD 
patients. However, herbal remedies can cause liver toxicity and IBD itself is associated with 
disorders of the liver and biliary tract. Thus, knowledge of CAM use will enable HCPs to 
better monitor patients and their response to treatment. Patients with a chronic disease who 
use CAM do not reject conventional medicine, nor do they have an unrealistic hope of a cure, 
but generally consider it a component of self-care [155]. In studies III and IV, IBD patients 
expressed concerns about the uncertain nature of their disease and wanted to have personal 
control over it [156]. The encounters between IBD patients and HCPs during which CAM 
was discussed indicate a need for change. A good encounter should be person-centred with 
sensitivity and empathy on the part of the HCP, allowing the patient an opportunity to ask 
questions and express emotion [139]. This was underlined by the IBD patients in study III 
who wished to be asked about CAM in order to start a dialogue. HCPs must be aware of this 
to meet the patient’s needs and create a good encounter The introduction of CAM education 
in nursing and medical school would improve this situation. 
Study III demonstrated that IBD patients felt that HCPs treated them in a disparaging manner 
and did not take them seriously when they wanted to discuss CAM. Interestingly, this finding 
contradicts the result of study II, where HCPs emphasized the importance of treating IBD 
patients with respect when they spoke about their CAM use. This indicates a communication 
gap between HCPs and IBD patients, leading to uncertainty that could be interpreted by the 
patients as a disparaging manner. Another reason for the communication gap could be that in 
Sweden, patients frequently report being encountered in a wrong or disrespectful manner 
[138]. Furthermore, in an international survey of eleven countries Sweden was found to have 
the most problems in terms of patient-centred care, access and coordination [157]. Swedish 
healthcare has substantial potential for improvement, although the patient’s position has 
recently been strengthened by a new law that highlights the concept of person-centred care. 
Following the implementation of the “Being open” policy in UK [158] there has been a 
reduction in the number of complaints and litigation. However, the reaction of patients in 
encounters is not always predictable, thus HCPs need guidance, training and support to cope 
with these challenges [159]. 
7.2.3 Implications for clinical practice 
Patients with IBD should be asked about their CAM use and a standard questionnaire could 
be a valuable instrument for assisting HCPs to initiate a dialogue. Nurses have an essential 
role in communicating about and monitoring CAM use in patients with IBD. HCPs need 
education and training to communicate about CAM, answer patients’ questions and 
recommend safe and effective CAM methods. IBD patients’ experiences of CAM could 
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enhance HCPs’ awareness of and improve communication about CAM, leading to a good 
HCP - patient relationship. 
7.2.4 Further research 
This thesis has provided new ideas for future research on IBD and CAM. 
 Create and evaluate a standard questionnaire regarding IBD patients’ CAM use.  
 Perform research on dietary changes in patients with IBD. 
 Investigate the sub-group of patients who had high scores in all RFIPC items in study 
IV. Why did these patients score so high on disease related concerns? 
 Conduct research on patients with IBD by means of an integrative approach. 
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8 CONCLUSIONS 
 Patients with IBD use CAM in an attempt to achieve improvement and well-being. 
 HCPs’ attitudes to CAM were mainly positive, although a problematic aspect was 
their lack of knowledge and evidence. They required education about CAM. 
 HCPs respected the decision of patients with IBD to use CAM. 
 Patients with IBD stated that HCPs were reluctant to discuss CAM, although they 
wished to be asked about CAM use and start a dialogue.  
 Patients with IBD perceived being treated in a disparaging manner and not taken 
seriously when wishing to discuss CAM. They found it easier to discuss CAM 
treatment with nurses than physicians. 
 Patients with IBD considered dietary changes an important CAM treatment with 
positive effects on their condition and sought knowledge about CAM because they 
wanted to make their own choices and live a normal life. 
 Patients using CAM generally had more disease related concerns compared with non-
users. 
 IBD affects the whole of everyday life, especially the family and the self. 
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9 SUMMARY IN SWEDISH 
Bakgrund  
Ulcerös kolit (UC) och Crohns sjukdom (CD) är inflammatoriska tarmsjukdomar 
(Inflammatory Bowel Disease=IBD) som drabbar mag-tarmkanalen och förlöper med 
perioder av ökad aktivitet (skov) växlande med perioder utan inflammation (remission). De är 
livslånga sjukdomar med symtom som i hög utsträckning påverkar det dagliga livet. I Sverige 
är knappt 61,200 personer drabbade av UC och CD. De flesta insjuknar mellan 15-30 år men 
alla åldrar kan drabbas med en jämn fördelning mellan könen. Komplementära och 
alternativa metoder (KAM) som till exempel homeopati, kinesisk medicin, meditation, 
hypnos, naturläkemedel och kiropraktik ingår inte i den konventionella hälso- och 
sjukvården. Det är vanligt att patienter med kroniska sjukdomar såsom IBD använder KAM. 
Forskningsrådet för Arbetsliv och Socialvetenskap uppmanar till forskning om KAM. Goda 
kunskaper ökar patienternas trygghet, och en ökad medvetenhet om KAM kan leda till en 
förbättrad kommunikation mellan IBD patienter och sjukvårdspersonal som i sin tur leder till 
en förbättrad vårdkvalitet. 
Syfte 
Syfte med avhandingen var att undersöka användning och förekomst av KAM hos patienter 
med IBD, samt att undersöka attityder till och erfarenheter av KAM hos patienter, läkare och 
sjuksköterskor. Vidare avsågs att undersöka IBD patienters sjukdomsspecifika oro relaterat 
till KAM användning. 
Studie I var en kontrollerad tvärsnitts- och multicenterstudie. Data från patienter vid 12 IBD 
kliniker i Sverige insamlades med hjälp av frågeformulär. Syftet var att studera i vilken 
omfattning patienter med IBD i Sverige använder KAM i jämförelse med en 
normalpopulation, vilka typer av KAM som används samt anledningen. 
I studien deltog 648 patienter med IBD. Av dessa IBD-patienter hade 48.3% använt någon 
form av KAM under det senaste året jämfört med 53.5% av personerna i kontrollgruppen. De 
vanligaste använda KAM metoderna hos IBD patienter jämfört med kontrollgruppen var 
massage som användes av 21.3% jämfört med 31.4% i kontroll gruppen, naturläkemedel 
användes av 18.7% av IBD patienterna jämfört med 21.3% i kontrollgruppen, för avslappning 
var motsvarande siffror 10.5% och 11.6% och yoga 8% och 9.6%, akupunktur 7.6% och 
8.9% och samtalsterapi 7.3% jämfört med 6.2, kiropraktik användes av 5.4% respektive 
5.7%. 
Studie II var en intervjustudie där sjukvårdspersonal fick beskriva sina erfarenheter och sin 
inställning till KAM. I studien deltog 16 läkare och sjuksköterskor, som arbetade med IBD 
patienter. Resultatet visade att IBD sjuksköterskor och läkare hade förtroende för och en 
positiv inställning till KAM, särskilt när KAM användes som komplement till konventionell 
medicin. De intervjuade upplevde att patienter sökte och testade olika KAM metoder. 
Deltagarna uppgav att de ansåg att KAM hade en plats inom hälso- och sjukvården, vilket 
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indikerar en acceptans för KAM. Men även attityder som utgjorde ett hinder för KAM 
rapporterades, såsom avsaknad av evidens. Några av de intervjuade uppvisade en restriktiv 
hållning och ansåg KAM vara onödigt, medan ett fåtal var skeptiska. 
Studie III var en intervjustudie där 15 IBD patienter tillfrågades om sina erfarenheter av 
KAM och hur de upplevde sjukvårdens bemötande i samband med användandet. Resultatet 
visade att patienter med IBD vill bli tillfrågade och vill ha en dialog om KAM. De kände sig 
ibland hånade och upplevde sig inte bli tagna på allvar när de ville diskutera KAM. Hälso- 
och sjukvårdspersonal behöver bli medveten om detta för att kunna bemöta och förstå IBD 
patientens behov. IBD patienterna upplevde att det var lättare att diskutera KAM med 
sjuksköterskor jämfört med läkare. Detta resultat understryker IBD sjuksköterskans viktiga 
roll i att kommunicera och monitorera IBD patienternas KAM användande. Hälso- och 
sjukvårdspersonal bör bli medveten om att IBD patienterna betraktar kostförändringar som en 
viktig KAM behandling. 
Studie IV var en kontrollerad tvärsnitts- och multicenterstudie. Data från 645 IBD patienter 
vid 12 IBD kliniker i Sverige insamlades med hjälp av frågeformulär. Syftet var att undersöka 
IBD patienters sjukdomsspecifika oro relaterat till KAM. Patienterna besvarade ett 
studiespecifikt frågeformulär med frågor om KAM, sociodemografiska och sjukdomspecifika 
data, samt frågeformuläret Rating Form of Inflammatory Bowel Disease Patients Concerns 
(RFIPC). RFIPC består av 25 frågor som patienten besvarar på en VAS skala från 0-100 
angående hur oroliga de är gällande en viss aspekt. I frågeformuläret fanns även en öppen 
fråga "Är det något mer som bekymrar dig?" vilken patienter fick svara på med egna ord. Av 
de som deltog använde 313 patienter KAM och de uttryckte mer oro avseende 15 av de 25 
frågorna i RFIPC frågeformuläret jämfört med de patienter som ej använde KAM. KAM 
användandet var relaterat till yngre ålder och kvinnligt kön. Via den öppna frågan framkom 
att inflammatorisk tarmsjukdom påverkar hela livet och att IBD patienterna upplevde oro för: 
familjen och jaget, sjukdomsbördan och omkringliggande faktorer 
Slutsatser 
KAM är vanligt förekommande hos svenska patienter med IBD och de använde KAM för att 
uppnå förbättring och välbefinnande. Hälso- och sjukvårdspersonalens attityder för KAM var 
i huvudsak positiva men de upplevde att de saknade utbildning och kunskap om KAM. 
Hälso- och sjukvårdspersonalen respekterade att patienterna använde KAM men IBD 
patienterna upplevde att personalen ibland var ovillig att diskutera KAM. Patienterna menade 
att de behandlades på ett nedsättande sätt och inte togs på allvar när de ville diskutera KAM. 
IBD patienterna ansåg att kostförändringar var en viktig KAM behandling med positiv effekt 
på deras tarmsjukdom. KAM användare bland IBD patienter hade generellt högre 
sjukdomsrelaterad oro jämfört med de som inte använde KAM och IBD påverkade det 
dagliga livet, speciellt familjen och jaget.  
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